Prostate Cancer

Products in the pipeline for prostate cancer, bladder cancer, stress urinary incontinence, chronic prostatitis/chronic pelvic pain syndrome, hypoactive sexual desire disorder.

To help you maximize your AUA experience, Urology Times’ editorial board and other thought leaders have pored over hundreds of abstracts to identify the key trends and can’t-miss research from this year’s meeting.

Statins may improve outcomes in hormone-sensitive prostate cancer, and one possible mechanism responsible may have been discovered.

The findings could help clinicians differentiate between slow-growing and aggressive tumors

The FDA has granted clearance to a hydrogel spacer for prostate cancer patients undergoing radiotherapy.

Final analysis of a phase III trial shows abiraterone acetate (ZYTIGA) plus prednisone extended overall survival compared to placebo plus prednisone in chemotherapy-naive men with mCRPC.

Recent phase II results point to the efficacy of the prostate cancer agent enzalutamide (XTANDI) when compared with bicalutamide (Casodex).

Men with prostate cancer who meet the criteria for active surveillance and undergo delayed radical prostatectomy after a period of active surveillance do not have a higher risk of adverse pathology compared with men with similar pre-treatment biopsy features who undergo immediate prostatectomy.

Charles J. Ryan, MD, recently presented the final analysis of the COU-AA-302 study of abiraterone acetate (ZYTIGA) versus placebo.

Christopher Amling, MD, describes strategies to reduce skeletal-related morbidity, including lifestyle changes, calcium and vitamin D supplementation, and pharmacologic therapy.

An iodine-125 low-dose-rate brachytherapy boost outperformed dose-escalated external beam radiotherapy boost in achieving biochemical progression-free survival in men with unfavorable risk prostate cancer, according to results of a recent multicenter trial.

The major organizations representing urologists are continuing their push for congressional approval of legislation designed to reform the operations of the U.S. Preventive Services Task Force, which in May 2012 recommended against PSA-based screening for prostate cancer.

Results presented at the EAU Annual Congress bolster the Prolaris test’s efficacy in determining disease aggressiveness.

Other highly read UT articles this month include a large comparison of robotic and open RP, answers to your questions about coding for prostate biopsy, and several studies about risks for low and high T.

The AUA, Large Urology Group Practice Association (LUGPA), and American Association of Clinical Urologists (AACU) would like to see the U.S. Preventive Services Task Force (USPSTF) revamp the methods it uses to develop recommendations on prostate cancer screening and other preventive care, and the three associations are now backing legislation that would do just that.

New, large-scale studies on active surveillance, IMRT complications, and robotic versus open prostatectomy were among the highlights of this year’s Genitourinary Cancers Symposium.

The review “represents the best available evidence for the morbidity and cost profile” of robot-assisted versus open radical prostatectomy, says one of the study’s authors.

Multiparametric MRI of the prostate with subsequent targeted biopsy shows promise for improving the identification of men on active surveillance for low-risk prostate cancer who require definitive treatment, according to researchers from the Vancouver Prostate Centre, Vancouver, BC.

Urologists with higher surgical volumes, especially in robotic procedures, are more likely to recommend immediate treatment than active surveillance in men with low-risk prostate cancer, according to a recent study.

Use of targeted magnetic resonance/ultrasound fusion biopsy (“targeted biopsy”) resulted in the diagnosis of significantly more high-risk prostate cancers and significantly fewer low-risk cancers compared with a standardized systematic biopsy technique, reported the authors of a new study from the National Cancer Institute.

GI complications add more than $3,000 to the cost of care for a Medicare beneficiary, researchers report.

The use of PSA is not straightforward. It’s not simple or easy. But the last time I checked, we physicians went to school for a long time so that we could explain complicated problems to our patients.

In this interview, Patrick H. McKenna, MD, former chairman of the AUA’s Judicial & Ethics Committee, discusses self-referral as well as the AUA expert witness program, conflicts of interest, and live surgical demonstrations.

African-American men with very low-risk prostate cancer being followed on active surveillance are at significantly higher risk for disease upgrading on subsequent biopsy compared to Caucasian men, according to analyses of prospectively collected data from the Johns Hopkins Active Surveillance registry.

A recent UCLA study suggests that physicians need to improve treatment counseling for patients with prostate cancer, a leading expert says.